Market Cap
$112.0M
NMRA
Neumora Therapeutics, Inc.
$0.4999 ▼ -9.11%
Prev close $0.5500Market cap$112.0M
ConsensusStrong Buy
12-mo target$6.14 (+1128.8%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)22 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on NMRA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
50 funds
Inst. Value
$81.8M
Inst. Activity
22 buys / 10 sells
Insider Activity
$0.00 buy / $701.6K sell
Insider Net $
-$701.6K
Social Sentiment
43° Neutral
SEC Reports
7
Press Releases
3
Price chart 30d -63.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Short Volume: NMRA — 69.8% short (0.9M / 1.4M)
Short: 942,966 | Exempt: 34,792 | TRF Vol: 1,350,689 | Short Ratio: 69.8% | Off-exchange volume (dar
Aug 21, 2026 Insider
Aurora Daljit Singh acquired via exercise 20,553 shares
See Remarks @ $0.7200 ($14.8K)
Aug 21, 2026 Insider
Aurora Daljit Singh sold 20,553 shares
See Remarks @ $1.59 ($32.8K)
Aug 21, 2026 Insider
Aug 20, 2026 SEC Aurora Daljit Singh acquired via exercise 21,055 shares
See Remarks @ $0.7200 ($15.2K)
Director Daljit Singh Aurora filed a Form 144 notice to sell 134,452 shares (~$203,584) via a broker-assisted cashless e
144 — Impact 5/10
Aurora Daljit Singh, an officer of Neumora Therapeutics, filed a Form 144 notice of intent to sell 146,706 shares of com
144 — Impact 5/10
Neumora Therapeutics reported Q2 2026 results with a net loss of $43.1M ($0.23 per share), in line with consensus estima
8-K — Impact 4/10
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhi
Impact 7/10
Analyst ratings buy % +12.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
80% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 13, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jun 18, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jun 16, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jun 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Aug 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Jul 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Jun 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| May 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Apr 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Mar 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Feb 1, 2026 | 4 | 7 | 3 | 1 | 0 | 73% |
Price targets
Where 7 covering analysts think NMRA trades over the next 12 months.
$6.14 +1128.8% upside Strong Buy
Current$0.4999 Low$3.00 Median$5.00 High$14.00 7 analysts
$3.00$14.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +81.8%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 1 bullish, 3 bearish, 0 mixed, 3 neutral · avg impact 4.6/10.Plus 3 press releases.
BEARISH1445/10
Director Daljit Singh Aurora filed a Form 144 notice to sell 134,452 shares (~$203,584) via a broker
Aug 20, 2026
BEARISH1445/10
Aurora Daljit Singh, an officer of Neumora Therapeutics, filed a Form 144 notice of intent to sell 1
Aug 17, 2026
NEUTRAL8-K4/10
Neumora Therapeutics reported Q2 2026 results with a net loss of $43.1M ($0.23 per share), in line w
Aug 14, 2026
NEUTRALPRESS-RELEASE4/10
Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
short_volume
Short Volume: NMRA — 69.8% short (0.9M / 1.4M)
Short: 942,966 | Exempt: 34,792 | TRF Vol: 1,350,689 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: NMRA — 60.6% short (0.5M / 0.8M)
Short: 486,974 | Exempt: 31,316 | TRF Vol: 803,259 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: NMRA — 61.6% short (1.1M / 1.8M)
Short: 1,091,370 | Exempt: 0 | TRF Vol: 1,772,957 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: NMRA — 70.5% short (0.6M / 0.9M)
Short: 647,461 | Exempt: 0 | TRF Vol: 918,351 | Short Ratio: 70.5% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: NMRA — 74.8% short (1.5M / 2.0M)
Short: 1,514,467 | Exempt: 158,917 | TRF Vol: 2,024,032 | Short Ratio: 74.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.19 | $-0.21–$-0.17 | 45.1% | +5.8% | 4↑ 2↓ | $0.0B | 9 |
| Next Q | $-0.17 | $-0.20–$-0.13 | 50.4% | +6.7% | 4↑ 2↓ | $0.0B | 9 |
| Current FY | $-0.87 | $-0.94–$-0.65 | 39.9% | +5.3% | 5↑ 2↓ | $0.0B | 9 |
| Next FY | $-0.67 | $-0.97–$-0.33 | 23.2% | +9.5% | 5↑ 2↓ | $0.0B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.192 | — |
| 7d ago | $-0.205 | +0.013 |
| 30d ago | $-0.204 | +0.012 |
| 60d ago | $-0.207 | +0.015 |
| 90d ago | $-0.234 | +0.042 |
Institutional ownership
Which big funds own NMRA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $81.8M total value (48,104,977 shares) as of 2026-Q2. Top holders: BlackRock,, SOFTBANK, VANGUARD. Net buying activity: 22 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,791,869 | $13.2M | 16.2% | DOUBLED +279.3% |
| SOFTBANK GROUP CORP. | 6,090,301 | $10.4M | 12.7% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,669,585 | $7.9M | 9.7% | — |
| TUDOR INVESTMENT CORP ET AL | 3,835,200 | $6.5M | 8.0% | ADD +75.8% |
| FMR LLC | 3,498,869 | $5.9M | 7.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,607,289 | $4.4M | 5.4% | DOUBLED +139.9% |
| TWO SIGMA INVESTMENTS, LP | 2,244,829 | $3.8M | 4.7% | — |
| STATE STREET CORP | 1,582,119 | $2.7M | 3.3% | DOUBLED +296.8% |
| TUDOR INVESTMENT CORP ET AL | 1,356,147 | $2.3M | 2.8% | ADD +75.8% |
| RENAISSANCE TECHNOLOGIES LLC | 1,262,304 | $2.1M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 2,054,316 | 7,791,869 | +279.3% | $13.2M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 1,086,865 | 2,607,289 | +139.9% | $4.4M |
| STATE STREET CORP | DOUBLED | 398,719 | 1,582,119 | +296.8% | $2.7M |
| TUDOR INVESTMENT CORP ET AL | ADD | 771,418 | 1,356,147 | +75.8% | $2.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | 184,836 | 894,791 | +384.1% | $1.5M |
| CITADEL ADVISORS LLC | DOUBLED | 343,586 | 828,933 | +141.3% | $1.4M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 516,182 | 823,583 | +59.6% | $1.4M |
| NORTHERN TRUST CORP | DOUBLED | 196,881 | 800,571 | +306.6% | $1.4M |
| VANGUARD FIDUCIARY TRUST CO | ADD | 535,033 | 706,667 | +32.1% | $1.2M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 354,850 | 577,615 | +62.8% | $982.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 37 transactions. Net -$701.6K — $0.00 bought, $701.6K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Aurora Daljit Singh | See Remarks | EXERCISE | 20,553 | $0.7200 | $14.8K |
| Aug 21, 2026 | Aurora Daljit Singh | See Remarks | SELL | 20,553 | $1.59 | $32.8K |
| Aug 21, 2026 | Aurora Daljit Singh | See Remarks | EXERCISE | 21,055 | $0.7200 | $15.2K |
| Aug 21, 2026 | Aurora Daljit Singh | See Remarks | SELL | 21,055 | $1.60 | $33.6K |
| Aug 20, 2026 | Pinto Joshua | President & CEO | AWARD | 500,000 | — | — |
| Aug 20, 2026 | Milligan Michael Lee | See Remarks | AWARD | 175,000 | — | — |
| Aug 20, 2026 | Duncan Jason | See Remarks | AWARD | 375,000 | — | — |
| Aug 20, 2026 | Aurora Daljit Singh | See Remarks | EXERCISE | 67,741 | $0.7200 | $48.8K |
| Aug 20, 2026 | Aurora Daljit Singh | See Remarks | SELL | 67,741 | $1.51 | $102.6K |
| Aug 20, 2026 | Aurora Daljit Singh | See Remarks | EXERCISE | 21,685 | $0.7200 | $15.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NMRA.
Shares short
6,979,674
Settlement Sep 15, 2026
Change vs prior
-13.1%
Semi-monthly cycle
Days to cover
9.0
At avg daily volume
Of shares outstanding
≈3.7%
Estimate — not % of float
All NMRA filing & press-release reports (10)
- 144 reportAug 20, 2026
- 144 reportAug 17, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportJul 27, 2026
- PRESS-RELEASE reportJul 27, 2026
- 8-K reportJun 15, 2026
- DEFA14A reportApr 17, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 16, 2026